Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain [PDF]
, 2002 Ruth Luthi‐Carter
openalex +1 more source
Aggregate formation inhibits proteasomal degradation of polyglutamine proteins [PDF]
, 2002 Lisette G. G. C. Verhoef
openalex +1 more source
Biochemical analysis to study wild-type and polyglutamine-expanded ATXN3 species. [PDF]
PLoS OneQuinet G, Paz-Cabrera MC, Freire R.
europepmc +1 more source
Loss of FIC-1-mediated AMPylation activates the UPRER and upregulates cytosolic HSP70 chaperones to suppress polyglutamine toxicity. [PDF]
PLoS GenetVan Pelt KM, Truttmann MC.
europepmc +1 more source
L-arginine in patients with spinocerebellar ataxia type 6: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. [PDF]
EClinicalMedicineIshihara T +11 more
europepmc +1 more source
Modulation of polyglutamine-induced cell death by genes identified by expression profiling [PDF]
, 2002 Hiroto Kita
openalex +1 more source
Dendrite injury triggers neuroprotection in Drosophila models of neurodegenerative disease. [PDF]
Sci RepPrange SE +9 more
europepmc +1 more source
Disruption of the nascent polypeptide-associated complex leads to reduced polyglutamine aggregation and toxicity. [PDF]
PLoS OneDublin-Ryan LB, Bhadra AK, True HL.
europepmc +1 more source
Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis [PDF]
, 2002 Yaohui Chai +4 more
openalex +1 more source
Altered Metabolic Signaling and Potential Therapies in Polyglutamine Diseases. [PDF]
MetabolitesVohra A, Keefe P, Puthanveetil P.
europepmc +1 more source